NTLA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
7.7M
-49.1%
15.0M
-34.6%
23.0M
+67.0%
13.8M
-3.3%
14.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
7.7M
-49.1%
15.0M
-34.6%
23.0M
+67.0%
13.8M
-3.3%
14.2M
Operating Expenses
120.4M
+4.2%
115.6M
-5.0%
121.7M
-2.8%
125.3M
+0.8%
124.2M
R&D
82.6M
+2.3%
80.7M
-8.9%
88.7M
-6.4%
94.7M
-2.4%
97.0M
SG&A
37.8M
+8.6%
34.8M
+5.3%
33.1M
+8.4%
30.5M
+12.2%
27.2M
Operating Income
-112760000
-12.2%
-100532000
-1.8%
-98710000
+11.5%
-111477000
-1.3%
-109996000
EBITDA
-110678000
-12.6%
-98330000
-2.1%
-96330000
+11.7%
-109062000
-1.4%
-107522000
Net Income
-106634000
-10.8%
-96231000
-0.5%
-95786000
+5.5%
-101324000
-0.1%
-101255000
EPS (Basic)
$-0.80
+1.2%
$-0.81
+2.4%
$-0.83
+9.8%
$-0.92
+6.1%
$-0.98
EPS (Diluted)
$-0.80
+1.2%
$-0.81
+2.4%
$-0.83
+9.8%
$-0.92
+6.1%
$-0.98
Shares (Diluted)
133.5M
+12.7%
118.5M
+2.1%
116.1M
+5.4%
110.2M
+6.2%
103.7M
Intellia Therapeutics (NTLA) โ€” Financials